Clinical trial · Interventional
Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer
Clinical Study of Aprepitant and Ondansetron Monotherapy or Combination in the Treatment of Postoperative Nausea and Vomiting in Thyroid Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The vast majority of patients treated prophylactically with "first-line" antiemetics in the 5-hydroxytryptamine (5-HT3) receptor antagonist class still have significant PONV. Combination therapies with different pharmacologic bases have the potential to reduce the incidence of PONV. This study is a multicenter, three-arm, prospective study to evaluate the efficacy and safety of aprepitant and ondansetron, monotherapy or in combination, in the prevention of nausea and vomiting after surgery for thyroid cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aprepitant 125 mg | Drug | — | UNRESOLVED |
| Ondansetron 8mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- Ondansetron group
- description
- Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
- interventionNames
- Drug: Ondansetron 8mg
- type
- OTHER
- label
- Arepitant group
- description
- Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
- interventionNames
- Drug: Aprepitant 125 mg
- type
- EXPERIMENTAL
- label
- Combined treatment group
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients aged 18-80 years; 2. Voluntary enrollment in the study and signing the informed consent form; 3. Diagnosed with thyroid cancer and needing surgical treatment; Exclusion Criteria: 1. Patient has depression, history of chronic pain, insulin-dependent diabetes mellitus I or II, history of severe vomiting; 2. history of prior thyroid or neck surgery; 3. Cases in which surgery requiring sternotomy is anticipated; 4. History of long-term hormone use, period of immunosuppressive therapy; 5. pre-operative voice changes or laryngoscopic confirmation of vocal cord paralysis; 6. Pregnant or breastfeeding patients; 7. Patients who are allergic to any of the study medications; 8. Patients who have received any sedative, hypnotic, anxiolytic, opioid, steroid or other antiemetic medication within 24 hours prior to the procedure; 9. Patients taking or planning to take a combination of drugs such as rifampicin, carbamazepine, phenytoin or other drugs that strongly induce CYP3A4 activity; 10. patients with other malignant tumors; 11. Patients with hypothyroidism; 12. Participating or planning to participate in other clinical studies.
References
Publications (0)
Data not yet available